drugset / Trial / NCT00817986
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arbaclofen Placarbil | Small molecule | 20 mg | Oral |
| Subject | Arbaclofen Placarbil | Small molecule | 30 mg | Oral |
| Subject | Arbaclofen Placarbil | Small molecule | 40 mg | Oral |
Indications
No indication recorded.